Amphastar Pharmaceuticals, Inc. (AMPH)
NASDAQ: AMPH · Real-Time Price · USD
25.90
-0.12 (-0.46%)
Nov 18, 2025, 4:00 PM EST - Market closed
Amphastar Pharmaceuticals Revenue
Amphastar Pharmaceuticals had revenue of $191.84M in the quarter ending September 30, 2025, with 0.33% growth. This brings the company's revenue in the last twelve months to $723.31M, down -0.03% year-over-year. In the year 2024, Amphastar Pharmaceuticals had annual revenue of $731.97M with 13.59% growth.
Revenue (ttm)
$723.31M
Revenue Growth
-0.03%
P/S Ratio
1.69
Revenue / Employee
$356,659
Employees
2,028
Market Cap
1.19B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 731.97M | 87.57M | 13.59% |
| Dec 31, 2023 | 644.40M | 145.41M | 29.14% |
| Dec 31, 2022 | 498.99M | 61.22M | 13.98% |
| Dec 31, 2021 | 437.77M | 87.92M | 25.13% |
| Dec 31, 2020 | 349.85M | 27.49M | 8.53% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
AMPH News
- 6 days ago - Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - Accesswire
- 10 days ago - Amphastar Pharmaceuticals, Inc. (AMPH) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 12 days ago - Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2025 - Accesswire
- 23 days ago - Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 6th, 2025 - Accesswire
- 2 months ago - After Protracted Sell-Off, Amphastar Looks Like A Value Pick - Seeking Alpha
- 2 months ago - Amphastar Pharmaceuticals to Present at the 2025 Wells Fargo Healthcare Conference - Accesswire
- 3 months ago - Amphastar Secures FDA Nod For Iron Sucrose Injection, Analysts Eye Major Sales Momentum - Benzinga
- 3 months ago - Amphastar Pharmaceuticals Bolsters Proprietary Pipeline Through Exclusive Licensing Agreement with Nanjing Anji Biotechnology Co., Ltd. - Accesswire